drugset / Trial / NCT01199146
Abiraterone Post Ketoconazole for Prostate Cancer
Phase 2
Completed
42 enrolled
University of California, San Francisco
Cougar Biotechnology, Inc. · collabJohnson & Johnson · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, open label, single center study to evaluate the efficacy of abiraterone acetate (CB7630) administered to patients with castrate resistant prostate cancer who have experienced disease progression on ketoconazole. It is hypothesized that abiraterone will be active in patients who have experienced disease progression on ketoconazole
Timeline
- Start
- 2010-09-10
- Primary completion
- 2013-01-04
- Completion
- 2016-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |